Stachydrine is an anti-metastatic agent.

In vitro: The aim of a previous study was to investigate the effects of stachydrine (STA) on norepinephrine (NE) induced hypertrophy and the changes of calcium transients in neonatal rat cardiomyocytes. Results showed that NE treatment could increase protein synthesis, cell surface area, the expression level of β-MHC, and β/α-MHC ratio and these effects were attenuated by STA treatment. In addition, NE-induced hypertrophy was associated with accelerated decay of Ca2+-transient, increased phospholamban expression, increased Ca2+-transient amplitude, hyper-phosphorylation, increased intracellular cAMP level, as well as PKA overactivation. All of these effects could be inhibited by STA treatment significantly [1].

In vivo: The previous study evaluated the effect of stachydrine on the expression of caspase-9 and 12 in rats with unilateral ureteral obstruction. Results showed that the degree of renal interstitial fibrosis, serum creatinine, blood urea nitrogen, the renal tubular interstitial damage index, and expression of caspase-9 and 12 in the stachydrine-treatment groups was significantly decreased [2].

T23398

C7H13NO2·HCl

179.6

Stachydrine (hydrochloride);Stachydrine (hydrochloride) (471-87-4 free base)

Ethanol:≤10mg/mL
DMSO:15mg/ml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years